The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.

Article Details

Citation
Copy to clipboard

McAdam LC, Mayo AL, Alman BA, Biggar WD

The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.

Acta Myol. 2012 May;31(1):16-20.

PubMed ID
22655512 [ View in PubMed
]
Abstract

Deflazacort is the most commonly prescribed corticosteroid for the treatment of Duchenne muscular dystrophy in Canada. We review the long-term experience with deflazacort treatment at two centers in Canada; Montreal and Toronto. Deflazacort has benefitted both cohorts by prolonged ambulation, preserved cardiac and respiratory function, less scoliosis and improved survival. Common side effects in both cohorts include weight gain, decreased height and cataract formation. The Canadian experience supports the use of deflazacort in treating boys with Duchenne muscular dystrophy.

DrugBank Data that Cites this Article

Drugs